Gepotidacin – Oral Products
| Minimum Inhibitory Concentrations (mcg/mL) | Disk Diffusion (zone diameter in mm) | |||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Enterobacteralesa | ≤ 16 | 32 | ≥ 64 | ≥ 12 | 8-11 | ≤ 7 |
| Staphylococcus saprophyticus | ≤0.25 | - | - | ≥ 23 | - | - |
| Enterococcus faecalis | ≤4 | - | - | ≥ 14 | ||
S = susceptible; I = intermediate; R = resistant
a Clinical efficacy was shown for Escherichia coli, Klebsiella pneumoniae, and Citrobacter freundii complex.